

Clinical trials of ixabepilone based chemotherapy for advanced breast cancer (metastatic) in no longer responding to currently available chemotherapies

TrialResults-center www.trialresultscenter.org

1 epothilones

Trial	Treatments	Patients	Trials design and methods
ixabepilone (on top capecitabine) vs no ixabepilone			
Sparano , 2010 n=NA follow-up:	ixabepilone (40 mg/m ²) intravenously on day 1) plus capecitabine (2,000 mg/m ²) orally on days 1 through 14) given every 21 days versus capecitabine alone (2,500 mg/m ²) on the same schedule) given every 21 days	patients with metastatic breast cancer previously treated with anthracycline and taxanes	Parallel groups open
Thomas , 2007 n=752 follow-up:	ixabepilone 40 mg/m ²) intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m ²) orally on days 1 through 14 of a 21-day cycle versus capecitabine alone 2,500 mg/m ²) on days 1 through 14 of a 21-day cycle	patients with metastatic breast cancer progressing after anthracycline and taxane treatment	Parallel groups open

References

Sparano, 2010:

Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P, Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2010;28:3256-63. [20530276] [10.1200/JCO.2009.24.4244](https://doi.org/10.1200/JCO.2009.24.4244)

Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P, Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2010;28:3256-63. [20530276] [10.1200/JCO.2009.24.4244](https://doi.org/10.1200/JCO.2009.24.4244)

Thomas, 2007:

Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roch HH, Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. *J Clin Oncol* 2007;25:5210-7. [17968020] [10.1200/JCO.2007.12.6557](https://doi.org/10.1200/JCO.2007.12.6557)

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roch HH Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. *Breast Cancer Res Treat* 2010;122:409-18 [20454927] [10.1007/s10549-010-0901-4](https://doi.org/10.1007/s10549-010-0901-4)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.